CCR2 Polymorphism in Chronic Renal Failure Patients Requiring Long-Term Hemodialysis

Basit Öğe Kaydı
dc.authoridBagci, Gokhan/0000-0003-4554-2391
dc.authoridKucuk KURTULGAN, Hande/0000-0001-9172-3244
dc.contributor.authorSezgin, Ilhan
dc.contributor.authorKoksal, Binnur
dc.contributor.authorBagci, Gokhan
dc.contributor.authorKurtulgan, Hande Kucuk
dc.contributor.authorÖzdemir, Öztürk
dc.date.accessioned2025-01-27T20:20:29Z
dc.date.available2025-01-27T20:20:29Z
dc.date.issued2011
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective A number of chemokines and chemokine receptors are produced by intrinsic renal cells as well as by infiltrating cells during renal inflammation. The CCR2 chemokine receptor mediates leukocyte chemoattraction in the initiation and amplification phase of renal inflammation. The polymorphism, CCR2-V64I, changes valine 64 of CCR2 to isoleucine. We aimed to determine the frequency of CCR2-V64I polymorphism in patients with chronic renal failure requiring long-term hemodialysis. Methods and Patients The PCR-based restriction fragment length polymorphism (PCR-RFLP) technique was used to assess the gene frequencies of CCR2-641 in CRF patients (n=210) and healthy controls (n=139) in the current study. Results The frequencies of the CCR2 genotype were 0.68 for V/V, 0.28 for V/I, and 0.4 for I/I in the CRF patients and 0.81 for V/V, 018 for V/I and 0.1 for I/I in healthy controls. The distribution of the CCR2-V64I mutant genotype was significantly different between subjects with CRF and healthy control subjects (X2=7.197 and p=0.027). Conclusion We found that the CCR2-V64I polymorphism was significantly high in CRF patients. In addition to the contribution to disease pathogenesis, it was recently found that chemokines have therapeutic importance in chronic renal failure. The frequency of CCR2-V64I and other chemokine and chemokine receptor polymorphisms in renal pathologies must be further investigated in larger study populations and in different renal diseases.
dc.identifier.doi10.2169/internalmedicine.50.5119
dc.identifier.endpage2461
dc.identifier.issn0918-2918
dc.identifier.issn1349-7235
dc.identifier.issue21
dc.identifier.pmid22041342
dc.identifier.scopus2-s2.0-80455178539
dc.identifier.scopusqualityQ3
dc.identifier.startpage2457
dc.identifier.urihttps://doi.org/10.2169/internalmedicine.50.5119
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21724
dc.identifier.volume50
dc.identifier.wosWOS:000299378800003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherJapan Soc Internal Medicine
dc.relation.ispartofInternal Medicine
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCCR2 gene
dc.subjectchronic renal failure
dc.subjectchemokines
dc.titleCCR2 Polymorphism in Chronic Renal Failure Patients Requiring Long-Term Hemodialysis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu